KAHR Medical
Fusion Protein for the Treatment of Cancer and Autoimmune Diseases
Total raised
€30M
€29,588,810
Funding rounds
3
Investors
4
distinct backers
Active since
2013-08
latest 2020-02
Funding by year
EUR raised per yearSignals
High confidenceRaise-next likelihood22
base rate 53% for Series D+
- ▼ Dormant (no round in 3+ cohort gaps)
- ▲ Up-round momentum
- ▼ Low backer re-investment
Exit likelihood16
base rate 12% (2+ rounds)
- ▲ 3 rounds raised
- ▲ 21y since founding
Timing: dormant vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
3 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2020-02-25 | Series D+ | €17M | Flerie Invest | View deal → |
| 2015-12-01 | Growth/Late | €11M | DSC Investment,Korea Investment Partners,Mirae Asset Venture Investment | View deal → |
| 2013-09-01 | Seed | €2.1M | — | View deal → |
Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- Roivant Sciences€1.2BSwitzerland · Healthtech
- CMR Surgical€1.2BUK · Healthtech
- Trax€791MIsrael · Software
- Oura Health€779MFinland · Healthtech